{
  "docId": "019de073-a38b-741c-ac33-1ee77869cf6c",
  "docSlug": "1556a4546991601fbfe098864d52433b",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 36,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a vertical timeline/process flow to show the progression of clinical development alongside key de-risking milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a38b-741c-ac33-1ee77869cf6c/21",
  "deckHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c",
  "deckJsonHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c.json",
  "deckAnchorHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.15,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "In Vitro, In Vivo, Predictive Dose Modeling, Phase 1, CSF Concentration, Phase 1b Cognitive Challenge, Phase 2A, DPNP, Phase 2a, CIAS",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abeca16c-4292-44ab-998a-ad01652aa5e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.7,
        "y": 0.22
      },
      "kind": "list",
      "text": "Consistent PK-PD relationship, Confidence in active dose range, Complete CMC package, Excellent tolerability and safety, Multiple clinical cognitive signals, De-risked path forward",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62e87586-45c5-4f2b-bae1-74af62736e89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "RL-007: demonstrated pro-cognitive treatment for CIAS. 1. Pharma developed product in-licensed with extensive pre-clinical & clinical data package. 2. Human Phase 1 + 2 data show replicated, clinically significant learning and memory effects, consistent with broad pre-clinical pro-cognitive data. 3. Well tolerated (>500 subjects dosed), centrally acting oral drug. 4. Initial indication: cognitive impairment associated with schizophrenia (CIAS) is characterized by episodic learning and memory deficits - no approved treatment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "203d9706-b64f-48c7-a570-2e90a85e3f76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "RL-007: a de-risked pro-cognitive neuromodulator with excellent tolerability in humans",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a97e5c23-c259-4620-929b-1454bac5c0c1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "e416c360-075b-4539-9486-fc8d8a450768",
      "evidence": "Vertical timeline showing clinical development stages",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}